Yuriy Ostapenko

3.2k total citations · 1 hit paper
6 papers, 227 citations indexed

About

Yuriy Ostapenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yuriy Ostapenko has authored 6 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Yuriy Ostapenko's work include Cancer Genomics and Diagnostics (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). Yuriy Ostapenko is often cited by papers focused on Cancer Genomics and Diagnostics (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). Yuriy Ostapenko collaborates with scholars based in Ukraine, United States and South Korea. Yuriy Ostapenko's co-authors include Hyun Cheol Chung, Chie‐Schin Shih, Yelena Y. Janjigian, Akihito Kawazoe, Lin Shen, Shukui Qin, Sun Young Rha, Pooja Bhagia, Eric Van Cutsem and Yuxian Bai and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Yuriy Ostapenko

6 papers receiving 221 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

2023 213 citations Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuriy Ostapenko Ukraine	3	149	131	73	62	25	6	227
Udo Lindig Germany	10	210 1.4×	181 1.4×	134 1.8×	83 1.3×	19 0.8×	36	298
Nanfeng Fan China	9	152 1.0×	112 0.9×	74 1.0×	53 0.9×	7 0.3×	22	238
Arinilda Campos Bragagnoli Brazil	6	131 0.9×	159 1.2×	94 1.3×	44 0.7×	21 0.8×	15	244
Yohei Kubota Japan	5	98 0.7×	95 0.7×	52 0.7×	25 0.4×	14 0.6×	12	202
K.-W. Lee South Korea	7	242 1.6×	252 1.9×	131 1.8×	121 2.0×	37 1.5×	16	378
Irene Pecora Italy	9	99 0.7×	130 1.0×	75 1.0×	17 0.3×	8 0.3×	24	207
Akesu Sujie China	8	90 0.6×	114 0.9×	79 1.1×	13 0.2×	22 0.9×	17	180
Yoshiki Horie Japan	7	161 1.1×	180 1.4×	103 1.4×	13 0.2×	8 0.3×	30	266
Evgeny Gotovkin Russia	4	150 1.0×	113 0.9×	75 1.0×	46 0.7×	5 0.2×	4	200

Countries citing papers authored by Yuriy Ostapenko

Since Specialization

Citations

This map shows the geographic impact of Yuriy Ostapenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuriy Ostapenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuriy Ostapenko more than expected).

Fields of papers citing papers by Yuriy Ostapenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuriy Ostapenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuriy Ostapenko. The network helps show where Yuriy Ostapenko may publish in the future.

Co-authorship network of co-authors of Yuriy Ostapenko

This figure shows the co-authorship network connecting the top 25 collaborators of Yuriy Ostapenko. A scholar is included among the top collaborators of Yuriy Ostapenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuriy Ostapenko. Yuriy Ostapenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Janjigian, Yelena Y., Akihito Kawazoe, Jianming Xu, et al.. (2024). Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.. Journal of Clinical Oncology. 42(3_suppl). 286–286. 1 indexed citations

2.

Ostapenko, Yuriy, et al.. (2023). Laparoscopic and Open Liver Resections for Colorectal Cancer Liver Metastasis in the Ukrainian State Center. Cureus. 15(5). e38701–e38701. 2 indexed citations

3.

Janjigian, Yelena Y., Akihito Kawazoe, Yuxian Bai, et al.. (2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet. 402(10418). 2197–2208. 213 indexed citations breakdown →

4.

Bondarenko, Igor, Zoran Andrić, Yuriy Ostapenko, et al.. (2022). Abstract CT551: Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin®) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC). Cancer Research. 82(12_Supplement). CT551–CT551. 1 indexed citations

5.

Sangro, Bruno, Peter R. Galle, Robin Kate Kelley, et al.. (2022). Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4074–4074. 5 indexed citations

6.

Bulat, Iurie, Yuriy Ostapenko, Zanete Zvirbule, et al.. (2021). Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).. Journal of Clinical Oncology. 39(15_suppl). TPS9137–TPS9137. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact